Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab

Table 2

Results of separate subgroups of group A before and 6 months after initiation of treatment; mean number of affected peripheral (PS) and central segments (CS) of neovascularization; corrected distance visual acuity (CDVA).

		Before treatment			6 months after treatment; (1 month in group 4)
		CDVA	PS	CS	CDVA	PS	CS	𝑃
1	Pterygium (𝑛=6)	0.85 (±0.21)	8.5 (±5.12)	0	0.9 (±0.18)	6.66 (±4.49)	0	PS: 0.03
								CS: 0.2
2	NV after penetrating keratoplasty (𝑛=8)	0.02 (±0.04)	41.25 (±17.42)	1.75 (±1.78)	0.05 (±0.08)	30.5 (±11.37)	1.25 (±1.45)	PS: 0.001
								CS: 0.02
3	Other etiologies (𝑛=13)	0.14 (±0.17)	33.77 (±25.16)	7.76 (±6.76)	0.16 (±0.21)	27.61 (±19.78)	7.23 (±6.99)	PS: 0.000
								CS: 0.002
4	Preparation for penetrating keratoplasty (𝑛=1)	0.0001	14	0	0.001	7	0